Several months after the U.S. Department of Justice signed off on Microsoft’s plan to acquire AI developer Nuance, its watchdog counterpart across the pond is taking a closer look at the proposed…
In a counterclaim filing against MIT professor David Sabatini, his former mentee and Whitehead Institute colleague alleges he “coerced” her into sex and led a “highly sexualized” lab. She claimed his…
At CB Insights’ Future of Health Conference, Ginger CEO Russell Glass talked about how the company merged with Headspace to form a $3 billion mental health company and how to scale up a mental health…
A panel of FDA advisors said Reata Pharmaceuticals’ main drug, bardoxolone, did not prove effective at slowing the progression of chronic kidney disease in Alport syndrome. The FDA is scheduled to…
Praduman Jain Praduman Jain is CEO and founder of Vibrent Health, a digital health technology company powering the future of precision medicine. He is also the principal investigator of the Participant Technology Systems Center of the National Institutes of Health’s All of Us Research Program. https://medcitynews.com/author/pjain
Join startup innovators and established biopharma companies to discuss how digital tools can be leveraged in every aspect—from drug development and clinical trials to manufacturing and operations—in…
PharmStars, an accelerator for companies developing digital solutions for pharmaceutical companies, has graduated its first class of startups. The theme for this initial group was ‘innovation in…
Join us for the virtual MedCity INVEST Digital Health conference – September 20-23, 2021
RJ Tesi RJ Tesi, M.D., is the co-founder and CEO of INmune Bio (NASDAQ: INMB), a publicly-traded, clinical-stage biotechnology company developing therapies that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials, the DN-TNF product platform, call XPro™ and the Natural Killer Cell Priming …
Technology already exists in many forms that can reduce the impact of Covid-19 in marginalized communities, but it has largely been overlooked
